CLINICAL TRIALS PROFILE FOR TOFRANIL

All Clinical Trials for TOFRANIL

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00296725 ↗	Dichotic Listening as a Predictor of Medication Response in Depression	Completed	New York State Psychiatric Institute	Phase 1/Phase 2	1994-04-01	Depressed patients will have hearing tests and then be treated with up to three treatments (i.e., Fluoxetine, Imipramine) until remitted, to see whether test results predict specific outcomes.
NCT00404755 ↗	Dichotic Listening as a Predictor of Medication Response in Depression	Completed	New York State Psychiatric Institute	Phase 4	2006-07-01	This study will recruit 100 depressed patients to test whether the previous finding of an association between treatment response (with treatment groups including placebo, imipramine, and fluoxetine) and preferences of hemispheric laterality in perceptual processing are also found with a different type of commonly used anti-depressant, bupropion.
NCT00946764 ↗	To Demonstrate the Relative Bioavailability of Sandoz Inc. and Tyco Healthcare (Tofranil) 50 mg Imipramine Hydrochloride Tablets In Healthy Adults Volunteers Under Fasting Conditions	Completed	Sandoz	Phase 1	2005-07-01	To demonstrate the relative bioavailability of Sandoz Inc. and Tyco Healthcare (Tofranil) 50 mg imipramine hydrochloride tablets in healthy adult volunteers under fasting conditions.
NCT01028014 ↗	Medication Effects on Periurethral Sensation,Urethral Sphincter Activity and Pressure Flow Parameters	Completed	Astellas Pharma Inc	N/A	2010-04-01	Lower urinary tract symptoms such as urinary leakage and overactive bladder affect millions of American women. Women may develop these problems because the innervation of the muscles of the bladder and urethra are injured. Most research on treating these problems has focused on the abnormalities of the bladder muscle, but newer studies have shown abnormalities in the innervation and muscle function of the urethra. Women with these symptoms may benefit from treatment with medications to improve their urethral function. However, to truly understand what types of medications will help women with these symptoms, the investigators wish to study how these medications affect innervation and muscle function in healthy women who do not have lower urinary tract symptoms.
NCT01028014 ↗	Medication Effects on Periurethral Sensation,Urethral Sphincter Activity and Pressure Flow Parameters	Completed	University of Alabama at Birmingham	N/A	2010-04-01	Lower urinary tract symptoms such as urinary leakage and overactive bladder affect millions of American women. Women may develop these problems because the innervation of the muscles of the bladder and urethra are injured. Most research on treating these problems has focused on the abnormalities of the bladder muscle, but newer studies have shown abnormalities in the innervation and muscle function of the urethra. Women with these symptoms may benefit from treatment with medications to improve their urethral function. However, to truly understand what types of medications will help women with these symptoms, the investigators wish to study how these medications affect innervation and muscle function in healthy women who do not have lower urinary tract symptoms.
NCT01944657 ↗	Supplemental Transcranial Magnetic Stimulation (TMS) vs. Standard Medication Monotherapy for Treating Major Depression: An Exploratory Field Study	Withdrawn	Central Michigan University	N/A	2013-09-01	A. Introduction to the Problem This field experiment is intended to explore whether supplemental transcranial magnetic stimulation (TMS) is more effective than standard medication mono-therapy for the treatment of major depressive disorder. Transcranial magnetic stimulation (TMS) is now included in the practice guidelines of the American Psychiatric Association for the treatment of major depression. B. Importance of the Area of Study The safety, efficacy and value of TMS treatment has been established through the four-phase FDA approval process. The evidence of TMS safety and efficacy derives from multiple, peer reviewed, double-blind, randomized, control trials (RCT) with sham control as well as strict enrollment and methodological requirements. TMS is now used in actual clinical practice and there is an opportunity to extend laboratory research and typical, highly controlled field settings to applied settings. This study is designed to gather data on safety, efficacy and utility of TMS as it is used in clinical practice. C. Need for Additional Research Efficacy and safety of these interventions have been scientifically established and meta-analyses of these studies underscore the efficacy and safety of two treatment interventions to be employed in this study: 1) standard medication monotherapy and 2) standard medication therapy supplemented with TMS. However, many authors conclude that depression can be difficult to treat and there is an ongoing need for additional research. Depression remains a major public health problem.

Clinical Trial Conditions for TOFRANIL

Condition Name

Condition Name for TOFRANIL
Intervention	Trials
Dysthymia	2
Major Depressive Disorder	1
Urethral Sphincter Activity	1
1. Major Depressive Disorder	1

Condition MeSH

Condition MeSH for TOFRANIL
Intervention	Trials
Depression	4
Depressive Disorder, Major	3
Depressive Disorder	3
Dysthymic Disorder	2

Clinical Trial Locations for TOFRANIL

Trials by Country

Trials by Country for TOFRANIL
Location	Trials
United States	4

Trials by US State

Trials by US State for TOFRANIL
Location	Trials
New York	2
Maryland	1
Alabama	1

Clinical Trial Progress for TOFRANIL

Clinical Trial Phase

Clinical Trial Phase for TOFRANIL
Clinical Trial Phase	Trials
Phase 4	1
Phase 1/Phase 2	1
Phase 1	1

Clinical Trial Status

Clinical Trial Status for TOFRANIL
Clinical Trial Phase	Trials
Completed	4
Withdrawn	1

Clinical Trial Sponsors for TOFRANIL

Sponsor Name

Sponsor Name for TOFRANIL
Sponsor	Trials
New York State Psychiatric Institute	2
Sheppard Pratt Health System	1
Sandoz	1

Sponsor Type

Sponsor Type for TOFRANIL
Sponsor	Trials
Other	5
Industry	2